Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
resveratrol formulation
|
| gptkbp:acquiredBy |
GlaxoSmithKline
|
| gptkbp:activeIngredient |
resveratrol
|
| gptkbp:developedBy |
gptkb:Sirtris_Pharmaceuticals
|
| gptkbp:discontinued |
gastrointestinal side effects
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRT501
|
| gptkbp:intendedUse |
treatment of type 2 diabetes
treatment of metabolic disorders |
| gptkbp:relatedTo |
SIRT1 activation
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:bfsParent |
gptkb:Sirtris_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|